Alladapt Immunotherapeutics, Inc. announced that it has entered into a term loan agreement for the gross proceeds of $50 million on August 30, 2022. The transaction will include participation from new investor Hercules Capital, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.12 USD | -0.52% | +1.43% | +14.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.70% | 3.08B | |
+31.41% | 12.02B | |
+2.08% | 1.41B | |
-8.46% | 1.23B | |
+0.68% | 617M | |
+1.06% | 617M | |
+45.05% | 597M | |
-4.17% | 496M | |
+30.43% | 478M | |
+3.90% | 306M |
- Stock Market
- Equities
- HTGC Stock
- News Hercules Capital, Inc.
- Alladapt Immunotherapeutics, Inc. announced that it expects to receive $50 million in funding